-
China Grand Pharm's JV to buy shares in medical device firm
China Grand Pharmaceutical and Healthcare (00512) said its joint venture
company formed with East Ocean Capital (Hong Kong) Company Limited, an indirect
non-wholly owned subsidiary of controlling shareholder China Grand Enterprises
Incorporation, will subscribe in aggregate 1.04 million preferred shares of
Conavi Medical Inc. at about US$7.5 million.
The target company is incorporated in Canada, and is a medical device company with 
innovative cardiovascular and intravascular imaging technology.
The JV also obtains the twenty years exclusive distribution rights for the products of 
target company such "Foresight ICE" series and "Novasight Hybrid" series in the PRC
mainland, Hong Kong, Macau and Taiwan regions, and is responsible for the clinical trials
and registration work of the related products in the regions.

Comments

Post a Comment

Popular posts from this blog

-
CLSA lowers Beijing Ent Water (00371) to HK$6   CLSA cut its target price for Beijing Enterprises Water (BEW)(00371) by 8% to HK$6, and reiterated its "buy" rating.   The research house said BEW's share price has dropped 14% in the last two trading days. First, the 2017 earnings results are below expectations. Second, management is guiding for 20-25% net profit growth for 2018, versus 30% in the past few years. Management now has a cautious approach to water PPP (public-private partnership) projects, which is not  necessarily bad.   CLSA cut its 2018-19 earnings forecasts by 19%. At the current level, it believes many  of the negatives are already priced-in.
Read more
-
HSBC HOLDINGS Appoints Malaysia CEO as Asia-Pacific One-Belt-One-Road Biz Manager  HSBC HOLDINGS(00005.HK)    +1.150 (+1.574%)    Short selling $311.30M; Ratio 15.773%   announced that Malaysia CEO Mukhtar Hussain was appointed to the newly created position of head of Belt and Road initiative in Asia Pacific, effective from 1 July.
Read more
-
Image
WKK INTL (HOLD) (00532.HK)    +0.100 (+15.152%)      announced the results for its subsidiary, Taiwan Kong King, for the nine months ended September 2014. The unaudited combined after-tax net profit decreased 30.26% to $12.239 million, compared with the same period last year. Revenue amounted to $177 million.
Read more